# A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

> **NCT00586924** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 49 (actual)

## Conditions studied

- Hairy Cell Leukemia

## Interventions

- **DRUG:** Moxetumomab Pasudotox (CAT 8015)
- **DRUG:** Moxetumomab Pasudotox (CAT 8015)
- **DRUG:** Moxetumomab Pasudotox (CAT 8015)
- **DRUG:** Moxetumomab Pasudotox (CAT 8015)
- **DRUG:** CAT 8015 (Moxetumomab Pasudotox)
- **DRUG:** Moxetumomab Pasudotox (CAT 8015)

## Key facts

- **NCT ID:** NCT00586924
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-10
- **Primary completion:** 2015-05-06
- **Final completion:** 2015-05-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00586924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00586924, "A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00586924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*